Bleeding and overanticoagulation with danaparoid

The specific determinants of bleeding during danaparoid therapy are not well established. Danaparoid should be used with caution in patients with prior major bleeding and other patient-associated factors for increased bleeding risk listed in Patient-associated factors that increase bleeding risk with anticoagulant therapy; seek specialist haematologist advice.

No specific antidote is available to manage bleeding caused by danaparoid. Stop danaparoid if significant bleeding occurs and provide supportive treatment. Consider giving recombinant factor VIIa for life-threatening bleeding; seek specialist haematologist adviceFrontera, 2016.